NVAX
NOVAVAX INC
NASDAQ · Healthcare · Biotechnology · US
$10.11
+1.10%Sep 18, 2026, 22:45 UTC
Novavax (NVAX) shares closed at $10.11, up 1.1% from the previous trading day.
Source:Sep 18, 2026, 08:46 UTC
Novavax (NVAX) shares jumped 7.0% in the prior trading session on above-average trading volume.
Source:Aug 28, 2026, 12:30 UTC
Novavax's partners received approvals for the XFG-adapted Nuvaxovid COVID-19 vaccine formulation for the 2026-2027 vaccination season in the U.S., EU, and Japan.
Source:Aug 6, 2026, 12:00 UTC
Novavax reported total revenue of $57 million for the second quarter of 2026 and raised its full-year 2026 revenue framework and improved GAAP combined R&D and SG&A expense guidance by $10 million at the midpoint.
Jul 19, 2026, 15:52 UTC
Jianyi Biotechnology (a subsidiary of Shengde Group) signed a formal cooperation agreement with Polish CDMO company Mabion S.A. to jointly develop antibody-drug conjugates (ADCs) and target the European CDMO market.
Source: